";s:4:"text";s:5336:" Our next question comes from the line of Simon Baker of Redburn. And then as a final note, do bear in mind that we are operating already at a very high level in terms of our operating margin first half at 47%. About Us This, in turn, is expected to significantly lower triglycerides, leading to a potential reduction of cardiovascular events in the hypertriglyceridemic target population. Can you just clarify how much of that has been seen in 1H and what is implied for 2H and is 3% a fair estimate into 2021, just clarify that. And in terms of total prescriptions, Ozempic market share is slightly more than 26%. Avg. Or Karsten, do you want to comment on the U.S. growth?Yes.
The expectations for operating profit growth primarily reflects the sales growth outlook and continued investments in current and future growth drivers across the operating units. Despite the expected negative impact from COVID-19 in 2020, sales growth is still expected to be between 3% and 6%.The guidance reflects an expectation for continued robust sales performance of the GLP-1-based diabetes care products, Ozempic, Victoza and Rybelsus, the portfolio of new generation insulin and the biopharm products.
Novo's focus is to evaluate, acquire and explore gold properties. For further company information, visit Novo Nordisk on: www.novonordisk.com Investor presentation Personal Finance US insulin indexed NBRx development ET. Do you believe at this point in time that FDA has the capacity to handle regulatory process in six months if you decide to use the voucher?And then, secondly, if you decide to use the voucher, then you have to alert FDA, I think it's three months prior, which means that you need to make a writedown of the value of the voucher this year. And I think that is a rational way of going and that will most likely continue. And we have basically all our reps back in the field in the U.S. Home; Investoren IR News. Dual targeting of the GLP-1 and amylin satiety pathways in the brain, henceforth, holds the potential to form a strong future noninvasive treatment alternative to bariatric surgery in patients with high BMI indices. The weekly new-to-brand market share has reached 11% and the total Rybelsus prescription share is nearly 3%. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services.Hello, and welcome to the Q2 2020 Novo Nordisk A/S Earnings Conference Call. Under the programme initiated 6 August 2020, Novo Nordisk will repurchase B shares for an amount up to DKK 2.8 billion in the period from 6 August 2020 to 28 October 2020. We've already seen in the U.K. a big recent initiative on obesity, which is tied in with COVID, although it was in part preexisting. Also in June 2020, the results from the Phase Ib trial investigating AM833 in combination with semaglutide were announced. The 26-week Phase II monotherapy trial with AM833 investigated the safety, tolerability, efficacy in weight management among 706 people with obesity or overweight plus at least one weight-related comorbidity. For the first half of the year, total sales increased by 7%, which was driven by a solid sales growth of 12% in International Operations. Operating profit increased by 9% in Danish kroner and by 8% at constant exchange rates.
The AM833 phase 2 monotherapy trial and phase 1 combination with semaglutide trial decreased weight by 10.8% and 17.1% Karsten, on the COVID-19 savings?Yes. But we will see the data late this year and I guess during the course of next year.Just quickly on FORTE, the timing for the Q4 time line. The STEP one, three and four trials evaluated semaglutide in people with obesity or overweight with comorbidities, while STEP two evaluated semaglutide in overweight or obese people with type two diabetes.
Is that are we talking variable for the year for FORTE or...Our next question comes from the line of Wimal Kapadia of Bernstein. The information center provides a central hub for news, guidance and resources. Words such as 'believe', 'expect', 'may', 'will', 'plan', 'strategy', 'prospect', 'foresee', 'estimate', 'project', 'anticipate', 'can', 'intend', 'target' and other words and terms of similar meaning in connection with any discussion of future operating or financial performance identify forward-looking statements. repurchased a total of 21,953,179 B shares at an average share price of DKK 425.40 per B share equal to a transaction value of DKK 9,338,881,053.
